GRCE insider transaction filings
Grace Therapeutics, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-21. Screen GRCE transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 10 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings by 2 insiders — 126,837 shares, $270,102 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: purchase of 100,000 shares @ $2.14 ($214,000) by Kohli Prashant, filed 2026-09-10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Kohli Prashant — Chief Executive Officer, Director | 2 | 1 leg · 100,000 sh · $214,000 | — | 1 |
| Opaleye Management Inc. — 10% owner | 2 | 3 legs · 26,837 sh · $56,102 | — | — |
| DAVIS A BRIAN — Director | 1 | — | — | 1 |
| DelAversano Robert J — Principal Financial Officer | 1 | — | — | 1 |
| Kottayil George — Director | 1 | — | — | 1 |
| Kumar Amresh — VP Program Management | 1 | — | — | 1 |
| Macdonald R. Loch — Chief Medical Officer | 1 | — | — | 1 |
| NEUGEBOREN EDWARD — Director | 1 | — | — | 1 |
Recent Form 4 filings — Grace Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-21 | 4 | DAVIS A BRIAN — Director | Grant/award (A) @ $0 | EDGAR |
| 2026-09-21 | 4 | NEUGEBOREN EDWARD — Director | Grant/award (A): 12,200 (derivative) @ $0 | EDGAR |
| 2026-09-21 | 4 | Kottayil George — Director | Grant/award (A): 12,200 (derivative) @ $0 | EDGAR |
| 2026-09-10 | 4 | Opaleye Management Inc. — 10% owner | Purchase (P): 9,393 @ $2.10 · Purchase (P): 5,836 @ $2.09 | EDGAR |
| 2026-09-10 | 4 | Kohli Prashant — Chief Executive Officer, Director | Purchase (P): 100,000 @ $2.14 | EDGAR |
| 2026-09-01 | 4 | DelAversano Robert J — Principal Financial Officer | Grant/award (A): 33,660 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Macdonald R. Loch — Chief Medical Officer | Grant/award (A): 54,690 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Kohli Prashant — Chief Executive Officer, Director | Grant/award (A): 267,160 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Kumar Amresh — VP Program Management | Grant/award (A): 35,760 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Opaleye Management Inc. — 10% owner | Purchase (P): 11,608 @ $2.09 | EDGAR |
| 2026-01-12 | 4 | Kavuru Vimal — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Kottayil George — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | NEUGEBOREN EDWARD — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | DAVIS A BRIAN — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Kottayil George — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Kavuru Vimal — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | NEUGEBOREN EDWARD — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | DAVIS A BRIAN — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Kumar Amresh — VP Program Management | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Macdonald R. Loch — Chief Medical Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | DelAversano Robert J — Principal Financial Officer | Grant/award (A): 20,130 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Kohli Prashant — Chief Executive Officer, Director | Grant/award (A): 225,400 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | D'Andrea Carrie — VP Clinical Operations | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Grace Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GRCE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →